Turning Point Therapeutics, Inc. named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs. In this role, Ms. Yeganegi will lead the global product development team responsible for Turning Point Therapeutics’ lead drug candidate, repotrectinib, and as head of Medical Affairs will support the ongoing physician education associated with the company’s three clinical-stage drug candidates in four ongoing clinical studies. Ms. Yeganegi will report to President and Chief Executive Officer Athena Countouriotis, M.D. Ms. Yeganegi has extensive experience building and leading oncology-focused global Medical Affairs teams, most recently as senior vice president and global program leader at Halozyme.